Avita Medical, Inc. short interest in 2022
In 2022, Avita Medical, Inc.'s disclosed short interest ran from 2.41% of shares outstanding on 14 Jan 2022 to 1.34% on 30 Dec 2022, a change of -1.07 percentage points. The year's high was 5.85% on 13 May 2022 and its low 0.59% on 14 Oct 2022, averaging 2.59% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.47 days on 31 May 2022. Full history: Avita Medical, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 2.41% (14 Jan 2022)
- End of year
- 1.34% (30 Dec 2022)
- Change
- -1.07 pp
- High
- 5.85% (13 May 2022)
- Low
- 0.59% (14 Oct 2022)
- Average
- 2.59%
- Highest days to cover
- 15.47 (31 May 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 2.41% | 5.64 | results (8-K) |
| 31 Jan 2022 | 2.75% | 5.10 | |
| 15 Feb 2022 | 3.28% | 7.24 | |
| 28 Feb 2022 | 3.99% | 9.31 | |
| 15 Mar 2022 | 3.72% | 4.43 | results (8-K) |
| 31 Mar 2022 | 3.42% | 4.09 | |
| 14 Apr 2022 | 3.53% | 7.91 | |
| 29 Apr 2022 | 4.44% | 7.74 | |
| 13 May 2022 | 5.85% | 8.60 | 10-Q filed |
| 31 May 2022 | 5.73% | 15.47 | results (8-K) |
| 15 Jun 2022 | 5.76% | 12.04 | |
| 15 Aug 2022 | 0.68% | 1.07 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 0.97% | 2.81 | |
| 15 Sep 2022 | 1.01% | 3.08 | |
| 30 Sep 2022 | 0.84% | 3.91 | |
| 14 Oct 2022 | 0.59% | 3.20 | |
| 31 Oct 2022 | 0.84% | 2.22 | |
| 15 Nov 2022 | 1.14% | 2.17 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 0.98% | 2.67 | |
| 15 Dec 2022 | 1.14% | 4.70 | |
| 30 Dec 2022 | 1.34% | 6.72 |
See also: Avita Medical, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.